Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Decline in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 908 shares, a drop of 51.7% from the February 26th total of 1,878 shares. Based on an average trading volume of 16,950 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

BOLT has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT opened at $4.38 on Friday. Bolt Biotherapeutics has a twelve month low of $3.91 and a twelve month high of $9.38. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average of $5.08 and a two-hundred day moving average of $5.31. The company has a market capitalization of $8.41 million, a price-to-earnings ratio of -0.25 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.43. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $0.67 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%. As a group, analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several large investors have recently modified their holdings of BOLT. Squarepoint Ops LLC lifted its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics during the third quarter valued at about $85,000. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics in the third quarter worth about $89,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $112,000. Finally, T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics in the fourth quarter worth approximately $208,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.